Q2 FY2026 · ended Jun 30, 2026 · Revenue $39.01M, -1.9% YoY · Filed Aug 6, 2026
Pacific Biosciences of California, Inc. (PACB) files with the SEC under industry code 3826, Laboratory Analytical Instruments. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $39.0 million and a net loss of $44.7 million. Free cash flow was -$37.1 million. As of Jun 30, 2026 it held $236.9 million in cash and investments and $61.8 million in total debt.
Revenue
$39.01M
-1.9% vs year-ago quarter
Net income
$-44.74M
-6.7% vs year-ago quarter
Operating cash flow
$-35.58M
-21.1% vs year-ago quarter
Free cash flow
$-37.14M
-24.1% vs year-ago quarter
EPS
$-0.14
+0.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
310.83M
+3.5% vs year-ago quarter
Net cash
$175.08M
Q2 FY2026
Operating margin
-83.5%
TTM
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- PACB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Menlo Park, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1299130
- Former names
- PACIFIC BIOSCIENCES OF CALIFORNIA INC (until Feb 5, 2013); NANOFLUIDICS INC (until Jul 28, 2004)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $39.0M | $37.2M | $44.6M | $38.4M | $39.8M |
| Operating income | -$44.6M | -$8.4M | -$41.2M | -$38.9M | -$44.9M |
| Net income | -$44.7M | -$8.3M | -$40.4M | -$38.0M | -$41.9M |
| Diluted EPS | -$0.14 | -$0.03 | -$0.13 | -$0.13 | -$0.14 |
| Operating cash flow | -$35.6M | -$44.7M | -$19.1M | -$18.7M | -$29.4M |
| Free cash flow | -$37.1M | -$47.7M | -$19.9M | -$18.8M | -$29.9M |
| Total assets | $751.9M | $782.4M | $784.1M | $803.2M | $825.5M |
| Total liabilities | $785.1M | $780.0M | $778.7M | $767.1M | $764.0M |
| Stockholders' equity | -$33.2M | $2.4M | $5.3M | $36.1M | $61.5M |
| Cash and investments | $236.9M | $276.0M | $279.5M | $298.7M | $314.7M |
| Total debt | $61.8M | $59.3M | $57.0M | $54.9M | $52.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Officer or director change
|
Nov 4, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Officer or director change, Regulation FD disclosure
|
Aug 5, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 9, 2026 | Jul 8, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
All 971 Pacific Biosciences of California, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.